company insight

ICCI – Prague has the green light for medical cannabis

The International Cannabis and Cannabinoids Institute (ICCI) offers a favorable legal climate, a strong professional background and a network of international contacts, experience and experts to its clients.  Its headquarters is in Prague, the capital city of the Czech Republic, a Member State of the European Union. 

SHL Group details its approach to the challenges of emerging formulations

It started as a project uniting outstanding experts from the scientific community, patient organizations and the investment company Dioscorides Global Holdings. As a recognized center of excellence, it cooperates with Charles University, the Czech University of Life Sciences in Prague, Masaryk University in Brno, Mendel University in Brno, Hebrew University in Jerusalem and many other institutions and companies around the world.

ICCI’ primary mission is to research the various uses of medical cannabis and has all the right preconditions for doing so. The team of specialists is comprised of both physicians and experts in healthcare systems, as well as leading experts with direct experience with scientific teams of the United Nations Organization, government bodies and organizations. All of this is supported by strong liaisons with patient organizations. It is this combination of experience and relationships along with a thorough understanding of various methods of treatment with cannabis and cannabinoids that provides ICCI unique know-how to react on the rapid changes in legislative processes in individual nations. ICCI offers deep understanding of the possibilities of medical cannabis for the needs of patients, particularly those that modern medical science may have failed to serve. Our efforts with cannabis-based medicine are always based on the needs of the patient and requirements of the examining physician. Our educational efforts provide the foundation needed for disseminating the knowledge needed by all stakeholders in this dynamic area of medical science and law.

ICCI offers a unique complex opportunity for everyone wanting to understand and utilize the opportunities that medical cannabis offers.

It is a modern hub that brings order to the disruptive technology that medical cannabis represents, and gives it meaning that is both salient and relevant. The expertise of professionals from the International Cannabis and Cannabinoids Institute and the consultative services that they provide are designed and appropriate for investors, physicians and pharmaceutical companies alike. Its advantage is in this comprehensiveness of our team and its activity. We offer to our clients and partners not only the specific experiences of medical cannabis patients, but also that of the physicians who prescribe it and research and development professionals who study this complex herb. Our experience also benefits hospital managers searching for a path towards efficient yet effective treatment. Not the least of which, the International Cannabis and Cannabinoids Institute benefits government bodies and organizations working on legislative processes in their respective countries that aim to make medical cannabis accessible to the public.

ICCI is the largest private investment in the Czech Republic into medical research in recent years. According to ICCI’s cooperating professor, Lubomír Hanuš from Hebrew University in Jerusalem, the potential of medical cannabis is enormous. “We know that marijuana has tetrahydrocannabinol a cannabidiol, but people don’t realize that various chemovars of cannabis may provide different effects,“ he explains. This is indicative of the fact that cannabis holds within further substances that offer anticarcinogenic effects. Through its research efforts, ICCI aids in understanding this plant and preparing from it needed medicine and innovative treatment methods to benefit every patient. Through its knowledge of law and the organization of healthcare systems, ICCI’s experience in this area enables stakeholders to speed up the legislative process by months and years, and their synchronization with the needs of medical science.

The institute thus removes all possible barriers preventing the development of research on the possibilities of medical cannabis and its utilization. Cooperation with the International Cannabis and Cannabinoids Institute enables everyone with an interest in researching medical cannabis to gain the background and facilities of a top international team, patient experiences and the organizational background of a strong scientific institution.

The Prague institute is a unique place for those who see the future of medical science in the area of biomedicine, and are searching for a platform for investment, sharing, development or education in this area. Thus, in golden Prague, the green light shines for everyone wanting to quickly forge a pathway to the future.

Share this article

Go to article: Home | Mapping the MindGo to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: EditorialGo to article: Biocorp Company InsightGo to article: BiocorpGo to article: ContentsGo to article: Fisher Clinical ServicesGo to article: Malvern Panalytical Company InsightGo to article: Malvern PanalyticalGo to article: NewsGo to article: Gerteis Company InsightGo to article: GerteisGo to article: The Pharma Industry BriefingGo to article: Mattler ToledoGo to article: MedelpharmGo to article: HPV vaccines: a decade of progressGo to article: Nipro PharmaPackagingGo to article: PfanstiehlGo to article: Hereditary Alzheimer’s: could rare genes hold the clue to a cure?Go to article: SGSGo to article: Capsugel Company InsightGo to article: CapsugelGo to article: Could a unique brain fingerprint predict a drug’s effectiveness?Go to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: Genetic studies: a powerful tool for testing combination therapiesGo to article: Nelson Lab Company InsightGo to article: Nelson LabGo to article: Abiogen PharmaGo to article: The Express Scripts story; super-pharmacies and the US drug industryGo to article: B Medical SystemsGo to article: Daiichi JitsugyoGo to article: LaudaGo to article: Is a lack of female participants skewing heart disease trial results?Go to article: EcocoolGo to article: HOF SonderanlagenbauGo to article: DiverseyGo to article: Why the German Centre for Diabetes Research changed its approach to handling dataGo to article: Dow Europe GmbH Company InsightGo to article: Dow Europe GmbHGo to article: QualiMetriXGo to article: How digital innovation is helping to drive transformation in regulatory affairs Go to article: DryceGo to article: ILC Dover IncGo to article: Pall BiotechGo to article: EventsGo to article: Event: Pharmpack EuropeGo to article: Pharma Support Services Ltd Company InsightGo to article: Pharma Support Services LtdGo to article: Unither PharmaceuticalsGo to article: Next issueGo to article: ButterworthGo to article: myLiquitab